3.5 Publications

May 29, 2019

Resolving Classification of PTEN Variants Using Gene-Specific ACMG/AMP Guidelines: A First Review of Curation Efforts by the ClinGen PTEN Variant Curation Expert Panel

2019 Clingen: Curating the Clinical Genome, Tempus-authored – The ClinGen PTEN Variant Curation Expert Panel (VCEP) provides assessment regarding the pathogenicity of germline PTEN variants with respect to a PTEN Hamartoma Tumor syndrome (MIM+601728) phenotype using PTEN-specific variant classification criteria based on the 2015 ACMG/AMP framework. Of highest priority...

May 26, 2019

Transcriptome-based Cancer Type Prediction for Tumors of Unknown Origin

Journal of Clinical Oncology, Tempus-authored – Background: Tumors of unknown origin occur in approximately 5% of newly diagnosed cancers and are difficult to treat without establishing the tissue type from which they derive. Establishing tumor origin guides standard of care treatment for several NCCN targeted therapy guidelines. Leveraging tissue sp...

May 26, 2019

Real-world Outcomes of Patients with Advanced Non-small Cell Lung Cancer (aNSCLC) and Autoimmune Disease (AD) Receiving Immune Checkpoint Inhibitors (ICIs)

Journal of Clinical Oncology, Tempus-authored – Background: Anecdotal and early evidence suggest ICIs are being used in patients with advanced malignancies and history of AD, despite such patients being typically excluded from traditional clinical trials. We compared the outcomes of patients with or without AD, all of whom had...

May 26, 2019

Real-world Characteristics and Outcomes of Patients with Advanced Non-small Cell Lung Cancer (aNSCLC) Receiving Immune Checkpoint Inhibitor

Journal of Clinical Oncology, Tempus-authored – Background: Immune Checkpoint Inhibitors (ICIs) were first approved for the treatment of aNSCLC in 2014, and since this time have seen rapid adoption in the marketplace. We sought to describe the characteristics of patients with aNSCLC receiving ICIs in the real-world, as well as t...

May 26, 2019

Characteristics of Patients Receiving Immune Checkpoint Inhibitors (ICI) in ASCO’s CancerLinQ

Journal of Clinical Oncology, Tempus-authored – Background: ICI’s have demonstrated significant clinical benefit since the first FDA approval in 2011 of ipilimumab for metastatic melanoma. Five additional ICI therapies have since been approved across several indications. The objectives of this study were to describe the clinical and demograph...

May 26, 2019

Real-world Prevalence of Autoimmune Disease (AD) Among Patients (pts) Receiving Immune Checkpoint Inhibitors (ICI) in ASCO’s CancerLinQ Database

Journal of Clinical Oncology, Tempus-authored – Background: Although pts with AD are routinely excluded from ICI clinical trials, evidence suggests they may be receiving ICI therapy once approved. We sought to understand the prevalence of AD among all pts receiving ICIs in real world clinical care, as well as i...

May 26, 2019

Overestimation of Tumor Mutational Burden (TMB) Using Algorithms Compared to Germline Subtraction

Journal of Clinical Oncology, Tempus-authored – Background: TMB is an emerging predictor of survival with immunotherapy. TMB is determined by taking the difference between somatic and germline datasets when tumor-normal pairs are available. In the case of commonly utilized tumor-only sequencing, additional steps are needed to estimate the somat...

May 26, 2019

Determining Clinical Relevance of Genomic Heterogeneity in an Ethnically Diverse Cohort of Newly Diagnosed Patients with Breast Cancer

Journal of Clinical Oncology, Tempus-authored – Background: The trajectory from early breast cancer to distant metastasis has not been precisely characterized. We are building an ethnically diverse, longitudinal cohort of prospectively ascertained breast cancer patients with integrated genomic, transcriptomic, epidemiological and clinical data, with the goal of identifyi...

May 26, 2019

Genomic Profiling of Residual Tumor after Neoadjuvant Chemotherapy for Breast Cancer

Journal of Clinical Oncology, Tempus-authored – Background: Patients who have residual disease after neoadjuvant chemotherapy (NAC) have a higher risk of metastatic recurrence. Residual disease likely includes therapy-resistant subclones of breast cancer cells, which untreated lead to metastases. The aim of this study was to identify additional adjuvant...

May 26, 2019

A Phase II Single-arm Study of Nivolumab and Ipilimumab (Nivo/Ipi) in Previously Treated Classic Kaposi Sarcoma (CKS)

Journal of Clinical Oncology – Background: CKS is an angioproliferative mesenchymal neoplasm causatively associated with human herpes virus 8 infection. Though recombinant IFNa is approved for treatment of AIDS-related KS, data is limited regarding the role of immune modulation in CKS therapy. Based on favorable responses in viral-induced cancers,...

Show More